Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.59 |
| ▸ | CPT1A | P50416 | 2/20 | 0.55 |
| ▸ | CPT1B | Q92523 | 2/20 | 0.55 |
| ▸ | CPT2 | P23786 | 1/20 | 0.55 |
| ▸ | WDR5 | P61964 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | ACLY | P53396 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1110224 | 0.96 | AKR1C3 (0.60) | AKR1C3CPT1ACPT1BCPT2WDR5 | |
| SCHEMBL1110453 | 0.88 | CHEK2 (0.48) | AKR1C3CPT1ACPT1BCPT2PGR | |
| SCHEMBL1110316 | 0.86 | PLAU (0.57) | PGRLMNASMN1; SMN2CYP3A4ALDH1A1 | |
| SCHEMBL1110670 | 0.85 | PGR (0.50) | AKR1C3CPT1ACPT1BCPT2PGR | |
| SCHEMBL1110252 | 0.84 | CHEK2 (0.49) | AKR1C3CPT1ACPT1BCPT2PGR | |
| SCHEMBL1320783 | 0.82 | KMT2A (0.58) | AKR1C3CPT1ACPT1BCPT2MEN1 | |
| SCHEMBL12115929 | 0.82 | CPT1A (0.50) | AKR1C3CPT1ACPT1BCPT2PGR | |
| SCHEMBL12115916 | 0.81 | GPR27 (0.70) | CPT1ACPT1BCPT2MEN1KMT2A | |
| SCHEMBL29561210 | 0.80 | POLB (0.71) | AKR1C3WDR5MEN1KMT2APGR | |
| SCHEMBL28280866 | 0.80 | POLB (0.71) | AKR1C3WDR5MEN1KMT2APGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| EP-2279173-A1 | NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009127723-A1 | NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-22 | — | — | WO | disclosed |
| WO-2009127723-A1 | NEW ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269761-A1 | ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | SULT2A1, UGT1A1, SLC5A1 | AKR1C3 457/4885CPT1A 174/4885CPT1B 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.